|Videos|September 22, 2021

Clinical Considerations for FMT for Recurrent Clostridioides Difficile

With fecal microbiota transplants (FMT) becoming a potential emerging therapy for these patients, here are some aspects to consider when treating.

Video Highlights

1:14 Sahil Khanna, MBBA, MS

4:29 Glenn Tillotson, PhD, FIDSA, FCCP

5:34 Anurag Malani, MD

Welcome to our series, 1 Big Question, which asks 1 question to the medical community and we get their feedback on an important infectious disease topic.

In this episode, our 1 Big Question is: One of the more interesting treatment areas within C diff is fecal microbiota transplants. What is your take on this potentially being used as a therapy in patients with recurrent c diff?

We interviewed, Sahil Khanna, MBBS, MS, is a Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, Glenn Tillotson, PhD, FIDSA, FCCP, GST Micro LLC, and Anurag Malani, MD, infectious diseases specialist, St. Joseph Hospital, and a fellow of Infectious Diseases Society of America (IDSA).

Check out our video to hear their insights.


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Measles Update: November 13, 2026
The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.
FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.